Mirati Therapeutics (MRTX) 10-K17 Mar 142013 FY Annual reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2013	Mar. 12, 2014	Jun. 30, 2013
Document and Entity Information	'	'	'
Entity Registrant Name	'MIRATI THERAPEUTICS, INC.	'	'
Entity Central Index Key	'0001576263	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Common Stock, Shares Outstanding	'	13,475,067	'
Entity Public Float	'	'	$15.40

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Current assets	'	'
Cash and cash equivalents	$14,235	$18,403
Short term investments	47,835	18,580
Other current assets	2,145	2,346
Total current assets	64,215	39,329
Other assets	0	139
Property and equipment, net	322	333
Total assets	64,537	39,801
Current liabilities	'	'
Accounts payable and accrued liabilities	5,245	5,340
Warrant liability	33,407	0
Total current liabilities	38,652	5,340
Other liability	0	45
Total liabilities	38,652	5,385
Commitments and contingencies	'	'
Stockholders' equity	'	'
Preferred stock, $0.001 par value, 10,000,000 shares authorized; none issued and outstanding at December 31, 2013 and 2012, respectively	0	0
Common stock, $0.001 par value; 100,000,000 authorized; 13,446,976 and 9,957,725 issued and outstanding at December 31, 2013 and 2012, respectively	13	10
Warrants	0	11,153
Additional paid-in capital	214,756	154,224
Accumulated other comprehensive income	9,507	9,520
Accumulated deficit	-198,391	-140,491
Total stockholders' equity	25,885	34,416
Total liabilities and stockholders' equity	$64,537	$39,801

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Statement of Financial Position [Abstract]	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	13,446,976	9,957,725
Common stock, shares outstanding	13,446,976	9,957,725

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Expenses	'	'
Research and development	$19,797	$15,081
General and administrative	11,144	5,394
Restructuring costs	1,025	0
Total operating expenses	31,966	20,475
Loss from operations	-31,966	-20,475
Other income (expense), net	-1,117	228
Change in fair value of warrant liability	-19,799	0
Loss before income taxes	-52,882	-20,247
Income tax expense (benefit)	-23	39
Net loss for the year	-52,859	-20,286
Unrealized loss on available-for-sale investments	13	0
Comprehensive loss for the year	($52,872)	($20,286)
Basic and diluted net loss per share (in dollars per share)	($4.78)	($3)
Weighted average number of shares used in computing net loss per share, basic and diluted (in shares)	11,057,040	6,762,985

CONSOLIDATED_STATEMENTS_OF_CHA

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock	Common stock warrants	Additional paid-in capital	Accumulated other comprehensive income	Accumulated deficit
In Thousands, except Share data, unless otherwise specified	Total	Common Stock	Common stock warrants	Additional paid-in capital	Accumulated other comprehensive income	Accumulated deficit
Beginning balance at Dec. 31, 2011	$27,305	$6	$6,247	$132,312	$8,945	($120,205)
Beginning balance (in shares) at Dec. 31, 2011	'	6,358,253	'	'	'	'
Increase (Decrease) in Stockholders' Equity	'	'	'	'	'	'
Net loss for the year	-20,286	'	'	'	'	-20,286
Stock-based compensation expense	2,009	'	'	2,009	'	'
Costs of reorganization	-15	'	'	-15	'	'
Issuance of common stock, net of costs	19,886	4	'	19,882	'	'
Issuance of common stock, net of costs (in shares)	'	3,593,819	'	'	'	'
Exercise of options for cash (in shares)	0	'	'	'	'	'
Issuance of warrants, net of costs	4,942	'	4,942	'	'	'
Net exercise of warrants	'	'	-36	36	'	'
Net exercise of warrants (in shares)	'	5,653	'	'	'	'
Foreign currency translation	575	'	'	'	575	'
Unrealized loss on investments	0	'	'	'	'	'
Ending balance at Dec. 31, 2012	34,416	10	11,153	154,224	9,520	-140,491
Ending balance (in shares) at Dec. 31, 2012	9,957,725	9,957,725	'	'	'	'
Increase (Decrease) in Stockholders' Equity	'	'	'	'	'	'
Net loss for the year	-52,859	'	'	'	'	-52,859
Reclassification of warrants	-16,194	'	-11,153	'	'	-5,041
Reclassification of stock option liability	1,369	'	'	1,369	'	'
Stock-based compensation expense	1,823	'	'	1,823	'	'
Issuance of common stock, net of costs	54,196	3	'	54,193	'	'
Issuance of common stock, net of costs (in shares)	'	3,337,500	'	'	'	'
Exercise of options for cash	540	'	'	540	'	'
Exercise of options for cash (in shares)	40,534	40,534	'	'	'	'
Exercise of warrants for cash	21	'	'	21	'	'
Exercise of warrants for cash (in shares)	'	2,896	'	'	'	'
Net exercise of warrants	2,586	'	'	2,586	'	'
Net exercise of warrants (in shares)	'	108,321	'	'	'	'
Unrealized loss on investments	-13	'	'	'	-13	'
Ending balance at Dec. 31, 2013	$25,885	$13	$0	$214,756	$9,507	($198,391)
Ending balance (in shares) at Dec. 31, 2013	13,446,976	13,446,976	'	'	'	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Operating activities	'	'
Net loss for the year	($52,859)	($20,286)
Non-cash adjustments reconciling net loss to operating cash flows	'	'
Depreciation of property and equipment	171	123
Stock-based compensation expense	1,823	2,009
Loss on disposal of property and equipment	40	0
Change in lease incentive liability	-70	85
Expense associated with fair value adjustment of warrant liability	19,799	0
Expense associated with fair value adjustment of share-based liability	1,369	0
Changes in operating assets and liabilities	'	'
Other current assets	340	-15
Accounts payable and accrued liabilities	-68	1,434
Cash flows used for operating activities	-29,455	-16,650
Investing activities	'	'
Purchases of marketable securities and term deposits	-68,408	-29,431
Disposal and maturities of marketable securities and term deposits	39,138	29,716
Purchase of property and equipment	-204	-230
Proceeds from disposal of property and equipment	4	0
Cash flows provided by / (used for) investing activities	-29,470	55
Financing activities	'	'
Proceeds from issuance of common stock, net of issuance costs	54,196	19,886
Proceeds from issuance of warrants, net of issuance costs	0	4,942
Proceeds from exercise of common stock options and warrants	561	0
Costs of reorganization	0	-15
Cash flows provided by financing activities	54,757	24,813
Increase (decrease) in cash and cash equivalents	-4,168	8,218
Effect of exchange rate changes on cash and cash equivalents	0	303
Cash and cash equivalents, beginning of year	18,403	9,882
Cash and cash equivalents, end of year	14,235	18,403
Income taxes paid	$35	$34

DESCRIPTION_OF_BUSINESS

DESCRIPTION OF BUSINESS	12 Months Ended
DESCRIPTION OF BUSINESS	Dec. 31, 2013
DESCRIPTION OF BUSINESS	'
DESCRIPTION OF BUSINESS	'
	Description of Business
	Mirati Therapeutics, Inc. (“Mirati” or the “Company”) is a clinical-stage biopharmaceutical company focused on developing a pipeline of targeted oncology products. The Company focuses its development programs on drugs intended to treat specific subsets of cancer patients with unmet needs.

	The Company has a wholly owned subsidiary in Canada, MethylGene, Inc. (“MethylGene”). MethylGene’s common stock was listed on the Toronto Stock Exchange from June 29, 2004 until July 26, 2013 under the ticker symbol “MYG”. The Company also has an indirect, wholly-owned subsidiary, MethylGene US Inc., which was incorporated in Princeton, New Jersey on December 20, 2011 and started business activity in 2012. The Company’s common stock has been listed on the NASDAQ Capital Market since July 15, 2013 under the ticker symbol “MRTX”. During the first half of 2013 the Company conducted the majority of its operations through MethylGene and MethylGene US Inc. As a result of the arrangement agreement discussed in Note 2 under the heading "Basis of Presentation," Mirati became the parent company during the last half of 2013. Refer to Note 2 for further discussion of the Company’s corporate structure.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	Summary of Significant Accounting Policies
	Basis of presentation
	These consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (GAAP). These consolidated financial statements include the accounts of the Company, Methylgene and MethylGene US Inc. All significant inter-company transactions, balances, revenue and expenses have been eliminated upon consolidation.
	Mirati was incorporated under the laws of the State of Delaware on April 29, 2013. The Company was created to enter into an arrangement agreement described below.
	On May 8, 2013, the Company's Board of Directors approved and the Company entered into an arrangement agreement with MethylGene. Subject to the terms and conditions of the arrangement agreement, which was consummated on June 28, 2013, the shareholders of MethylGene received one share of the Company's common stock in exchange for every 50 common shares of MethylGene, which had the effect of a 50 for 1 reverse split of the common shares pursuant to a court-approved plan of arrangement under Section 192 of the Canada Business Corporations Act. Such transaction is referred to herein as the Arrangement. In addition, all outstanding options and warrants to purchase common shares of MethylGene became exercisable on a 50-for-1 basis for shares of our common stock, and a proportionate adjustment was made to the exercise price or conversion price, as applicable. The accompanying financial statements and notes to the financial statements give retroactive effect to the reverse split of our common stock for all periods presented. Upon completion of the Arrangement, MethylGene became the Company's wholly-owned subsidiary. The shares of the Company's common stock issued at the closing of the Arrangement were issued in reliance upon the exemption from registration under Section 3(A)(10) of the Securities Act of 1933, as amended.
	These consolidated financial statements are presented in U.S. dollars, which effective January 1, 2013, is also the functional currency of the Company.
	Foreign currency translation
	Foreign currency transactions are initially recorded by the Company using the exchange rates prevailing at the date of the transaction. At the balance sheet date, monetary assets and liabilities denominated in foreign currencies are translated at the period-end rates of exchange. Non-monetary assets and liabilities are translated at the historical exchange rates. Exchange gains and losses arising from the translation of foreign currency items are included in other income (expense) in the consolidated statements of operations and comprehensive loss. The Company recognized net foreign exchange losses of $1.3 million and $12 thousand in other income (expense) in the consolidated statement of operations and comprehensive loss for the years ended December 31, 2013 and 2012, respectively.
	Cash and cash equivalents
	Cash is comprised of cash on hand and cash equivalents. Cash equivalents are comprised of short-term investment vehicles that are highly liquid and are readily convertible to known amounts of cash, which are subject to an insignificant risk of change in value, and have a maturity of less than 90 days from the date of purchase.
	Short-term investments
	Short-term investments consist of debt securities and other investment vehicles that are highly liquid and are readily convertible to known amounts of cash, which are subject to an insignificant risk of change in value, and have an original maturity of greater than 90 days. The majority of the Company's short-term investments are classified as available-for-sale investments. Certain of the Company's investments were purchased by its Canadian subsidiary prior to the Arrangement and are designated as held for trading investments as the investment portfolio is actively managed and their performance is evaluated on a fair value basis, in accordance with a documented risk management or investment strategy.
	The Company's short-term investments are carried at their fair market value based upon quoted market prices for these or similar instruments at the balance sheet date. Unrealized gains and losses on available-for-sale securities are reported as a component of accumulated other comprehensive income in stockholders' equity until realized. Unrealized gains and losses on trading securities are included in other income (expense) on the statement of operations and comprehensive loss. Debt securities are adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization, as well as realized gains and losses, are included in other income (expense).
	We assess our investments for potential other-than-temporary impairment based on factors including the length of time and extent to which the fair market value has been below our cost basis, the current financial condition of the investee and our intent and ability to hold the investment for a sufficient period of time to allow for any anticipated recovery in market value. If we conclude that an other-than-temporary impairment exists, we recognize an impairment charge to reduce the investment to fair value and record the related charge as a reduction of interest to other income (expense), net. We determined there were no other-than-temporary declines in the value of short-term investments as of December 31, 2013 and 2012.
	Property and equipment
	Property and equipment is stated at historical cost less accumulated depreciation and/or accumulated impairment losses, if any. Historical cost includes expenditures that are directly attributable to the acquisition of the items. Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. All other repairs and maintenance are charged to net loss during the financial period in which they are incurred.
	Depreciation of property and equipment is calculated using the straight-line method over the estimated useful lives of the assets, as follows:


	Computer equipment		3 years
	Office and other equipment		6 years
	Laboratory equipment		6 years
	Leasehold improvements		The lesser of the lease term or the life of the asset
	On disposal of property and equipment, the cost and related accumulated depreciation and impairments are removed from the consolidated financial statements and the net amount, less any proceeds, is included in net loss.
	Impairment of long-lived assets
	The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the long-lived asset, including its eventual residual value, is compared to the carrying value to determine whether impairment exists. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their estimated fair values. Fair value is estimated through discounted cash flow models to project cash flows from the asset. The Company recognized immaterial impairment charges related to its property and equipment for the year ended December 31, 2013 and no impairment charges for the year ended 2012.

	Reclassification of Warrants

	In 2011 and 2012, the Company issued common stock warrants in connection with the issuance of common stock through private placements (referred to as the 2011 Warrants and the 2012 Warrants). The exercise prices of the 2011 and 2012 Warrants were denominated in Canadian dollars. Upon the issuance of the 2011 and 2012 Warrants, the Company allocated the net proceeds to common stock and warrants based on their relative fair values, and calculated the fair value of the issued common stock warrants utilizing the Black-Scholes option-pricing model. The allocated fair value was then recorded as warrants within stockholders’ equity on the consolidated balance sheet. The fair value was not recalculated in periods subsequent to the date of issuance.

	The change in its functional currency to the U.S. dollar effective January 1, 2013 changed how the Company accounts for its warrants which have exercise prices denominated in Canadian dollars. Upon the change in functional currency, the Company classified these warrants as a current liability and recorded a warrant liability of $16.2 million which represents the fair market value of the warrants at that date in accordance with Accounting Standards Codification, or ASC, 815, “Derivatives and Hedging.” The initial fair value recorded as warrants within stockholders’ equity of $11.2 million was reversed. The change in fair value related to periods prior to January 1, 2013 of $5.0 million was recorded as an adjustment to accumulated deficit.

	At each reporting period subsequent to January 1, 2013, the Company adjusts the fair value of the warrant liability to the current fair market value and any corresponding increase or decrease to the warrant liability is recorded as income or expense, as appropriate, on the consolidated statement of operations and comprehensive loss as Change in fair value of warrant liability. The estimated fair value is determined using the Black-Scholes option-pricing model based on the fair value of the underlying common stock at the valuation measurement date, the remaining contractual term of the warrants, risk-free interest rates, expected dividends and expected volatility of the price of the underlying common stock. The fair value of the warrant liability was $33.4 million at December 31, 2013 and the Company recorded expense associated with the fair value adjustments of $19.8 million for the year ended December 31, 2013.

	Reclassification of Share-Based Compensation Liability

	The Company had granted stock options denominated in Canadian dollars under its 1997 Equity Plan to Canadian and United States, or US, based employees and directors until July 26, 2013. Following the delisting of the Company’s shares from the Toronto Stock Exchange, the options denominated in Canadian dollars that were granted to US-based employees and US-based directors are subject to liability accounting, in accordance with Accounting Standards Codification, or ASC, 718, “Compensation-Stock Compensation”. Such options are referred to herein as the Liability Options. The Company revalued the Liability Options as of July 26, 2013 and recorded a share-based compensation liability of $1.1 million with a corresponding reduction of additional paid-in capital.

	At each reporting period subsequent to July 26, 2013, the Company adjusted the fair value of the Liability Options and any corresponding increase or decrease to the liability was recorded as either a reduction of additional paid in capital or as stock compensation expense on the consolidated statement of operations and comprehensive loss, as appropriate. During the year ended December 31, 2013 these fair value adjustments resulted in an increase to additional paid in capital of $0.3 million and total stock compensation expense of $1.4 million. The estimated fair value is determined using the Black-Scholes option-pricing model based on the fair value of the underlying common stock at the valuation measurement date, the remaining life of the options, risk-free interest rates, expected dividends and expected volatility of the price of the underlying common stock.

	Effective November 30, 2013 the Company amended the agreements underlying the Liability Options such that the exercise price was converted from Canadian dollars to the equivalent US dollar exercise price by applying the exchange rate for the conversion of Canadian dollars into U.S. dollars based on the Bank of Canada’s noon buying rate for one U.S. dollar on the date the option was granted. The fair value of the Liability Options as of November 30, 2013 was $2.2 million and was reclassified from share-based compensation liability to additional paid-in capital.

	Stock-based compensation
	The Company has a stock option compensation plan in which the fair value of stock options granted is determined at the date of the grant using the Black-Scholes option-pricing model and is expensed over the vesting period of the options. Stock-based compensation is recognized using the accelerated graded vesting method. In determining the expense, the Company deducts the number of options that are expected to be forfeited at the time of a grant and revises this estimate, if necessary, in subsequent years if actual forfeitures differ from those estimated.
	Revenue recognition
	From time to time the Company may recognize revenue from research collaboration agreements and licensing arrangements. Upfront product and technology license fees under multiple-element arrangements are deferred and recognized over the period of such services or performance if such arrangements require on-going services or performance. Non-refundable amounts received for substantive milestones are recognized upon achievement of the milestone. Any amounts received prior to satisfying these revenue recognition criteria are recorded as deferred revenue. For the years ended December 31, 2013 and 2012 the Company did not recognize any revenue from collaborative agreements.
	Investment tax credits
	The Company's accounts include claims for investment tax credits ("ITCs") relating to scientific research and experimental development activities of the Company. The qualification and recording of these activities for investment tax credit purposes are established by the Canadian federal and Provincial Tax Acts and are subject to audit by the taxation authorities. Refundable ITCs are reflected as reductions of expenses or reductions of the cost of the assets to which they relate when there is reasonable assurance that the assistance will be received and all conditions have been complied with. The non-refundable ITCs are carried forward for a time and will be recognized when it is more likely than not that the Company will become subject to Canadian federal taxes, at which time, said ITCs are applied as a reduction of tax expense.
	Research and development expenses
	Research and development expenditures are charged to net loss in the period in which they are incurred and comprise of the following types of costs incurred in performing research and development activities and those incurred in connection with research and development revenue: salaries and benefits, stock-based compensation expense, allocated overhead and occupancy costs, clinical trial and related clinical manufacturing costs, contract services, and other outside costs.
	Income taxes
	Income taxes have been accounted for using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applicable to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance against deferred tax assets is recorded if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. For uncertain tax positions that meet "a more likely than not" threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements.
	Net loss per share
	Net loss per share is calculated by dividing the net loss of the Company by the weighted average number of shares of common stock outstanding during the year. The following table presents potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive:


			Year ended
			December 31,
			2013			2012
	Common stock options		495			15,663

	Common stock warrants		644,426			690,046

Total		644,921			705,709


Fair value measurements
We have certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.
The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance prioritizes the inputs used in measuring fair value into the following hierarchy:


•	Level 1- Quoted prices (unadjusted) in active markets for identical assets or liabilities;


•	Level 2- Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; and


•	Level 3- Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.
The following table summarizes the assets and liabilities measured at fair value on a recurring basis (in thousands):


	December 31,				Level 1				Level 2				Level 3
	2013
Assets
Cash and cash equivalents	$	14,235			$	12,431			$	1,804			$	—

Short-term investments	47,835				—				47,835				—

	$	62,070			$	12,431			$	49,639			$	—


Liabilities
Warrant liability	$	33,407			$	—			$	—			$	33,407

	$	33,407			$	—			$	—			$	33,407



	December 31,				Level 1				Level 2				Level 3
	2012
Assets
Cash and cash equivalents	$	18,403			$	2,825			$	15,578			$	—

Short-term investments	18,580				—				18,580				—

	$	36,983			$	2,825			$	34,158			$	—


Liabilities
Warrant liability	$	—			$	—			$	—			$	—

	$	—			$	—			$	—			$	—


There were no transfers between fair value measurement levels during the years ended December 31, 2013 and 2012.

The following table presents a rollforward of the fair value of the warrant liability which includes Level 3 measurements (in thousands):


		Year ended December 31,
		2013				2012
Warrant liability:
Balance at beginning of year:		$	—			$	—

Fair value upon reclassification of balance as of January 1, 2013		16,194				—

Change in fair value of warrant liability		19,799				—
included in net loss
Fair value of warrants exercised		(2,586		)		—

Balance at end of year:		$	33,407			$	—


The fair value of the warrant liability was calculated utilizing the Black-Scholes option-pricing model, using the following assumptions:



		1-Jan-13						31-Dec-13
		2011 Warrants			2012 Warrants			2011 Warrants			2012 Warrants
Risk-free interest rate		1.2	%		1.4	%		1.2	%		1.6	%

Volatility		107.5	%		116.3	%		112	%		115.9	%

Dividend yield		—			—			—			—

Expected life in years		3.3			4.9			2.3			3.9


Concentration of Credit Risk
The Company invests its excess cash in accordance with its investment policy. The Company's investments are comprised primarily of commercial paper and debt instruments of financial institutions, corporations, U.S. government-sponsored agencies and the U.S. Treasury. The Company mitigates credit risk by maintaining a well diversified portfolio and limiting the amount of investment exposure as to institution, maturity and investment type. Financial instruments that potentially subject the Company to significant credit risk consist principally of cash equivalents and short-term investments.
Segment Reporting
Operating segments are components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker for purposes of making decisions regarding resource allocation and assessing performance. To date, we have viewed our operations and managed our business as one segment operating primarily in the United States and Canada.

Use of Estimates
The preparation of the Company's consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts or revenue and expenses during the reporting period.
Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. Estimates and assumptions are reviewed quarterly. All revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.
Reclassifications
Certain reclassifications have been made to prior year balances in order to conform to the current year’s presentation. Specifically, restricted cash equivalents and marketable securities and interest and other receivables were classified as other current assets; non-current security deposits and restricted cash equivalents and marketable securities were classified as other assets; and current portion of other liability was classified as accounts payable and accrued liabilities.

RECENT_ACCOUNTING_PRONOUNCEMEN

RECENT ACCOUNTING PRONOUNCEMENTS	12 Months Ended
RECENT ACCOUNTING PRONOUNCEMENTS	Dec. 31, 2013
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]	'
RECENT ACCOUNTING PRONOUNCEMENTS	'
	Recent Accounting Pronouncements
	From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial position or results of operations upon adoption.
	In February 2013, the FASB issued authoritative guidance that requires an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, an entity is required to present, either on the face of the statement where net income is presented or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required under U.S. GAAP to be reclassified to net income in its entirety in the same reporting period. For other amounts that are not required under U.S. GAAP to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures required under U.S. GAAP that provide additional detail about those amounts. This guidance is effective for reporting periods beginning after December 15, 2012. We adopted this standard in the first quarter of 2013. The adoption of this standard did not have an impact on our financial position or results of operations.
	In July 2013, the FASB issued authoritative guidance regarding the presentation of unrecognized tax benefits when a net operating loss carryforward exists. This authoritative guidance amends current guidance. The amended guidance clarifies that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax position is disallowed. In situations where a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction or the tax law of the jurisdiction does not require, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. This amended guidance is effective prospectively for reporting periods beginning after December 15, 2013. The Company is evaluating the impact, if any, this guidance will have on its consolidated financial statements.

INVESTMENTS

INVESTMENTS	12 Months Ended
	Dec. 31, 2013
Investments, Debt and Equity Securities [Abstract]	'
INVESTMENTS	'
	Investments
	The following tables summarize our short-term investments (dollars in thousands):


			As of December 31, 2013
		Maturity (in years)	Amortized cost	Gross unrealized gains	Gross unrealized losses		Estimated fair value
	U.S. Treasury securities and debt securities of U.S. Government agencies(1)	2 years or less	3,001	—	(3	)	2,998

	Corporate debt securities(1)	2 years or less	31,319	—	(22	)	31,297

	Commercial paper(1)	1 year or less	8,485	12	—		8,497

	Guaranteed investment certificates (2)	1 year or less	5,046	—	(3	)	5,043

			47,851	12	(28	)	47,835



			As of December 31, 2012
		Maturity (in years)	Amortized cost	Gross unrealized gains	Gross unrealized losses		Estimated fair value
	Term deposits (2)	1 year or less	7,036	—	—		7,036

	Commercial paper (2)	1 year or less	5,026	—	—		5,026

	Guaranteed investment certificates (2)	1 year or less	6,518	—	—		6,518

			18,580	—	—		18,580

	(1) Investments are designated as available-for-sale investments.
	(2) Investments are designated as trading investments.

COLLABORATION_AGREEMENTS

COLLABORATION AGREEMENTS	12 Months Ended
COLLABORATION AGREEMENTS	Dec. 31, 2013
COLLABORATION AGREEMENTS	'
COLLABORATION AGREEMENTS	'
	Collaboration Agreements
	The Company is a party to collaboration agreements for which no revenue was recognized and no expenses were incurred for the two years ended December 31, 2013 and 2012. As of December 31, 2013 the Company no longer has any significant ongoing obligations in connection with such agreements.

OTHER_CURRENT_ASSETS

OTHER CURRENT ASSETS	12 Months Ended
	Dec. 31, 2013
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'
OTHER CURRENT ASSETS	'


	6. Other Current Assets	December 31,
		2013		2012
		(in thousands)
	Refundable research and development tax credits	809		593

	Interest and other receivables	306		507

	Prepaid expenses	667		779

	Commodity taxes and other	227		165

	Income taxes receivable	58		—

	Restricted cash	78		302

		$	2,145	$	2,346

PROPERTY_AND_EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
PROPERTY AND EQUIPMENT	'


	7. Property and Equipment	December 31,
		2013			2012
		(in thousands)
	Computer equipment	$	1,534		$	1,421

	Office and other equipment	122			89

	Laboratory equipment	1,794			1,794

	Leasehold improvements	53			56

		$	3,503		$	3,360

	Less: Accumulated depreciation	(3,181		)	(3,027		)
		$	322		$	333

	The Company incurred depreciation expense of $0.2 million and $0.1 million for the years ended December 31, 2013 and 2012, respectively.

ACCOUNTS_PAYABLE_AND_ACCRUED_L

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	'


	8. Accounts Payable and Accrued Liabilities	December 31,
		2013		2012
		(in thousands)
	Accounts payable	$	1,302	$	1,752

	Accrued expenses	2,335		2,754

	Accrued compensation and benefits	1,608		834

		$	5,245	$	5,340

RESTRUCTURING

RESTRUCTURING	12 Months Ended
	Dec. 31, 2013
Restructuring and Related Activities [Abstract]	'
RESTRUCTURING	'
	Restructuring
	On October 1, 2013, the Company announced a plan to terminate approximately 75% of its total workforce in connection with the closing of its Montreal, Quebec and Princeton, New Jersey offices (the "Restructuring"). The offices are being closed due to the Company consolidating its operations to the San Diego facility. Restructuring activities were reported as a separate line item in the accompanying consolidated statement of operations and comprehensive loss and were comprised of the following components (in thousands):


	Employee separation costs	$	911

	Facilities-related charges	50

	Asset impairments	40

	Other restructuring charges	24

	Total restructuring charges for the year ended December 31, 2013:	$	1,025


	Of the total restructuring costs incurred during the year ended December 31, 2013, all but $0.3 million of the costs were paid. The Company expects to incur additional restructuring costs of $0.3 million and $0.1 million associated with employee separation and facilities-related costs, respectively, during the first half of 2014.

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
STOCKHOLDERS' EQUITY	'
	Stockholders' Equity
	Common Stock
	As of December 31, 2013, the following shares were reserved for future issuance (in thousands):


		December 31,
		2013		2012
	Stock Option Plan	1,057		697

	Warrants to purchase common stock	2,540		2,733

	Employee Stock Purchase Plan	300		—

		3,897		3,430

	Warrants — issued and outstanding
	As of December 31, 2013 the following warrants for common stock were issued and outstanding:


	Issue date		Expiry date	Exercise price (stated in US Dollars as of 12/31/13)		Number of warrants outstanding
	April 4, 2011		April 4, 2016	$	7.01	1,461,541

	November 21, 2012		November 21, 2017	$	8.18	1,078,136

						2,539,677

	On November 21, 2012, the Company completed a private placement resulting in gross proceeds of $26.1 million. Under the terms of the offering the Company issued a total of 3,593,819 units at a subscription price of CND$7.25 (or $7.28, US Dollar equivalent), each unit consisting of one share of common stock and thirty one-hundredths (0.30) of a common stock purchase warrant, exercisable for a period of five years from the date of issuance at an exercise price of CND$8.70 (or $8.73, as converted) (representing 120% of the subscription price). The issuance costs of the units amounted to $1.3 million. The net proceeds were allocated to common stock and warrants based on their relative fair values.
	The fair value of the warrants issued on November 21, 2012 was estimated at the date of grant using the Black-Scholes option pricing model and the following assumptions: weighted average risk-free interest rate of 1.34%; dividend yield of zero; volatility factor of 115.5% and the expected life of the warrants of five years. The fair value allocated to the warrants amounted to $4.9 million and $19.9 million was recorded as an increase to common stock, net of costs.

STOCKBASED_COMPENSATION

STOCK-BASED COMPENSATION	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
STOCK-BASED COMPENSATION	'
	Stock-based compensation
	The Company has in place a stock option plan (the "Stock Option Plan") for the benefit of employees, directors, officers and consultants of the Company. In May 2013 our Board of Directors adopted the 2013 Equity Incentive Plan (the "2013 Plan"). The 2013 Plan was approved by our stockholders in connection with the Arrangement. The 2013 Plan is a continuation of and successor to the Stock Option Plan and no further grants will be made under the Stock Option Plan. As of December 31, 2013, there were 0.1 million stock options available to be issued.
	To date, stock-based compensation awards under either the Stock Option Plan or the 2013 Plan consist of incentive and non-qualified stock options. Stock options granted under each of the plans must have an exercise price equal to at least 100% of the fair market value of our common stock on the date of grant and generally vest over four years. The Stock Option Plan has contractual terms ranging from five to seven years and the 2013 Plan has contractual terms ranging from seven to ten years.

	In May 2013 the Company's Board of Directors adopted the 2013 Employee Stock Purchase Plan (the "ESPP"). The ESPP was approved by the Company's stockholders in connection with the Arrangement. As of December 31, 2013 the ESPP has not been implemented by the Company.


	The following table summarizes our stock option activity and related information for the year ended December 31, 2013:


		Number of		Weighted			Weighted-Average Remaining Contractual Term (years)	Aggregate Intrinsic Value (millions)
		options		average
				exercise
				price
	Options outstanding at December 31, 2012	559,812		$	15

	Granted	687,040		11.21

	Forfeited	(244,060	)	16.96

	Expired	(3,756	)	54.37

	Exercised	(40,534	)	13.9

	Options outstanding at December 31, 2013	958,502		$	11.18		6.6	$	5.4

	Options exercisable at December 31, 2013	251,981		$	10.57		5	$	1.7

	Options vested and expected to vest at December 31, 2013	896,778		$	11.18		6.5	$	5.1

	The total intrinsic value of stock options exercised was $0.2 million for the year ended December 31, 2013. The Company received total cash of $0.5 million for the exercise of options for the year ended December 31, 2013. There were no options exercised during the year ended December 31, 2012. The total fair value of options vested during the years ended December 31, 2013 and 2012 was $2.0 million and $2.4 million, respectively. Upon option exercise we issue new shares of our common stock.
	Total stock-based compensation expense by operating statement classification is presented below (in thousands):


		Year ended December 31,
		2013			2012
	Research and development expense	$	245		817

	General and administrative expense	2,947			1,192

		$	3,192		$	2,009

	In the years ended December 31, 2013 and 2012, no stock-based compensation expense was capitalized and there were no recognized tax benefits associated with the stock-based compensation charge.
	The fair value of options granted is estimated at the date of grant using the Black-Scholes option pricing model. The assumptions used for the specified reporting periods and the resulting estimates of weighted-average estimated fair value per share of options granted during those periods are as follows:


			Year Ended
			December 31,
			2013	2012
	Risk-free interest rate		2.00%	1.20%
	Dividend yield		—%	—%
	Volatility factor		112.90%	116.40%
	Expected life in years		7	4.4
	Weighted average estimated fair value per share		$11.21	$9.00
	The estimated fair value of the options is amortized to expense over the option's vesting period. The expected life of the options is based on historical data and current expectation and is not necessarily indicative of exercise patterns that may occur. Prior to the fourth quarter of 2013, the Company estimated the life of the options using historical data as well as various assumptions regarding the Company's expected progress on its development programs. As a result of the Arrangement, beginning in the fourth quarter of 2013, the Company began to estimate the expected term using the midpoint between the vesting date and the end of the contractual term. The Company believes this methodology is more appropriate as the Company's historical stock option activity is no longer predictive of future activity due to the Arrangement, the Company's listing on NASDAQ and subsequent delisting from the TSX and the organizational changes announced on October 1, 2013. Volatility is determined based on historical share price history, over a period similar to the expected life of the options, which may also not be necessarily indicative of the actual outcome. The risk-free interest rate is the rate for periods equal to the expected term of the stock option based on either the Canadian Treasury yield (for grants prior to July 16, 2013), or U.S. Treasury zero-coupon bonds (for grants after July 16, 2013).
	The total compensation cost not yet recognized as of December 31, 2013 related to non-vested option awards was $4.9 million which will be recognized over a weighted-average period of 1.9 years.

EMPLOYEE_BENEFIT_PLAN

EMPLOYEE BENEFIT PLAN	12 Months Ended
EMPLOYEE BENEFIT PLAN	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]	'
EMPLOYEE BENEFIT PLAN	'
	Employee Benefit Plan

	The Company has a defined contribution 401(k) plan (the Plan) for all employees. Employees are eligible to participate in the Plan if they are at least 21 years of age or older. Under the terms of the Plan, employees may make voluntary contributions as a percentage of compensation. The Company matches up to 4% of an employee's contributions, subject to a limit of $2,500 per year. During the years ended December 31, 2013 and 2012, expense associated with the Company's matching contribution totaled $34.6 thousand and $9.5 thousand, respectively.

OTHER_INCOME_EXPENSE_NET

OTHER INCOME (EXPENSE), NET	12 Months Ended
	Dec. 31, 2013
Other Income and Expenses [Abstract]	'
OTHER INCOME (EXPENSE), NET	'
	Other Income (Expense), Net
	The following table summarizes the components of other income (expense), net for the two years ended December 31, 2013 and 2012 (in thousands):


		Year ended December 31,
		2013			2012
	Interest and other income, net	$	203		$	240

	Loss on foreign exchange	(1,320		)	(12		)
		$	(1,117	)	$	228

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	Income Taxes
	The provisions for income tax expense (benefit), to the Company's wholly-owned subsidiary, MethylGene US Inc., are as follows (in thousands):


		Year ended December 31,
	Current:	2013				2012
	Federal	$	(23	)		$	30

	State	—				9

	Canada	—				—

	Total current tax expense (benefit)	$	(23	)		$	39


	Tax expense or benefit
	The differences between the effective income tax rate and the statutory tax rates during the years ended 2013 and 2012 are as follows (in thousands):


		Year Ended December 31,
		2013				2012
	Net loss before tax	$	(52,882	)		$	(20,247	)
	Statutory combined US federal and state tax rate (2012 - statutory combined Canadian federal and provincial tax rate)	39.83		%		26.9		%
	Statutory federal and provincial taxes	$	(21,063	)		$	(5,446	)
	Increase (decrease) in taxes recoverable resulting from:
	Effect of change in valuation allowance	8,537				5,145

	Non-deductible stock-based compensation	1,085				539

	Non-deductible warrant expenses for tax purposes	8,403				—

	Tax credits not taxable in Quebec	(96		)		(70		)
	Share issue costs - temporary difference	(184		)		(183		)
	Share issue costs - permanent difference	206				—

	Effect of foreign jurisdiction tax expense	—				39

	Differential in income tax rates of foreign subsidiary	3,059				—

	Other differences	30				15

	Income tax expense (benefit)	$	(23	)		$	39

	The combined statutory tax rate used for fiscal 2013 differs from the previous year due to the change in home jurisdiction under the consolidation process pursuant to implementation of the plan of arrangement on June 28, 2013.
	Deferred tax
	The following table summarizes the significant components of our deferred tax assets (in thousands):


		DECEMBER 31,
	Deferred tax assets	2013				2012
	Assets
	Tangible and intangible depreciable assets	$	874			$	853

	Manufactured drug product inventory to be used in research	1,459				757

	Provisions	93				30

	Financing fees	445				628

	Net operating loss carry forwards	13,099				6,883

	Scientific research and experimental development expenditures	5,766				4,245

Deferred tax assets	21,736				13,396

Valuation allowance	(21,736		)		(13,396		)
Net deferred tax assets	$	—			$	—

Total valuation allowance increased by $8.3 million for the year ended December 31, 2013. The Company has determined that it is more likely than not that it will not recognize the benefits of its US federal and state deferred tax assets and its Canadian federal and provincial deferred tax assets and, as a result, has established a full valuation allowance against its deferred tax assets as of December 31, 2013.
For Canadian federal income tax purposes, the Company's Canadian federal scientific research and experimental development expenditures amounted to $20.7 million and $15.2 million for the years ended December 31, 2013 and 2012, respectively and for provincial income tax purposes amounted to $22.4 million and $16.8 million for the years ended December 31, 2013 and 2012, respectively. These expenditures are available to reduce future taxable income and have an unlimited carry forward period. Scientific research and development expenditures are subject to verification by the taxation authorities, and accordingly, these amounts may vary by a material amount.
The Company also has accumulated share issue expenses that have not been deducted for income tax purposes amounting to approximately $1.7 million and $2.4 million for the years ended December 31, 2013 and 2012, respectively. The benefits of these expenses have not been recognized in the financial statements.
The Company's net operating loss carry forwards ("NOLs") for US federal and state income taxes were $2.8 million and $2.9 million, respectively, for the year ended December 31, 2013. There were no NOLs for US federal income taxes for the year ended December 31, 2012. The Company's NOLs for Canadian federal income tax purposes, were $44.1 million and $25.3 million at December 31, 2013 and 2012, respectively while the NOLs were $45.0 million and $25.6 million at December 31, 2013 and 2012, respectively, for provincial tax purposes.
The NOLs are available to offset future taxable income from US federal and state tax sources and Canadian federal and provincial tax sources and the tax benefits of which have not been recognized in the consolidated financial statements. The NOLs expire as follows (in thousands):


	US								Canada
	Federal				State				Federal		Provincial
Expires in:
2030	$	—			$	—			$	5,907	$	5,984

2031	—				—				7,059		7,066

2032	—				—				12,371		12,495

2033	2,838				2,919				18,717		19,467

	$	2,838			$	2,919			$	44,054	$	45,012

The future utilization of the US federal and state NOLs carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that may have occurred previously or may occur in the future. The Tax Reform Act of 1986 (the Act) limits a company's ability to utilize certain tax credit carryforwards and net operating loss carryforwards in the event of a cumulative change in ownerships in excess of 50% as defined in the Act. The Canadian Federal and Provincial Tax Acts maintain similar rules in the case of acquisition of control.
The Company files income tax returns in the US (federal and state) and Canada (federal and provincial). The Company’s U.S. operations have not been audited for any open taxation years. The Company has experienced losses for U.S. tax purposes and therefore, the taxation authorities may review any loss year, if and when the losses are utilized.

The Company's Canadian operations have been audited for provincial tax purposes up to and including December 31, 2009. For Canadian federal tax purposes, the Company remains subject to audit for the December 31, 2009 and subsequent taxation years. Where taxation years remain open, the Company considers it reasonably possible that issues may be raised or tax positions agreed to with the taxation authorities, which may result in increases or decreases of the balance of non-refundable ITCs and NOLs. However, an estimate of such increases and decreases cannot be currently made.
A reconciliation of the beginning and ending gross amounts of Canadian unrecognized tax positions adopted by the Company are as follows (in thousands):


	Federal								Provincial
	December 31,								December 31,
	2013				2012				2013		2012
Unrecognized tax positions, beginning of year	$	159			$	157			$	5	$	3

Gross decrease — current period tax positions	—				—				—		—

Gross increase — current period tax positions	—				2				—		2

Gross decrease — prior period tax positions	(48		)		—				—		—

Gross increase — prior period tax positions	18				—				18		—

Unrecognized tax positions, end of year	$	129			$	159			$	23	$	5

Included in the balance of unrecognized tax positions at December 31, 2013 and 2012, is $0.2 million and $0.2 million, respectively, that if recognized, would not impact the Company's income tax benefit or effective tax rate as long as the Company's deferred tax assets remain subject to a full valuation allowance. We do not expect any significant increases or decreases to the Company's unrecognized tax positions within the next 12 months.
The Company had no accrual for interest or penalties on tax matters as at December 31, 2013 and 2012 and the Company had no ongoing tax audits as of December 31, 2013.

INVESTMENT_TAX_CREDITS

INVESTMENT TAX CREDITS	12 Months Ended
	Dec. 31, 2013
INVESTMENT TAX CREDITS	'
INVESTMENT TAX CREDITS	'
	Investment Tax Credits
	The Company is eligible to claim Canadian federal and provincial ITCs for eligible scientific research and development expenditures. The Company records ITCs based on management's best estimates of the amount to be recovered and ITCs claimed are subject to audit by the taxation authorities and accordingly, may vary by a material amount.
	The Company recorded provincial refundable ITCs as a reduction of research and development expenditures of $0.9 million and $1.7 million (including a $1.1 million favorable adjustment resulting from a statutory audit), for the years ended December 31, 2013 and 2012, respectively.
	The Company's non-refundable Canadian federal ITCs amount to $4.1 million and $3.1 million at December 31, 2013 and 2012, respectively, and relate to scientific research and development expenditures, which may be utilized to reduce Canadian federal income taxes payable in future years. The benefits of the non-refundable Canadian federal ITCs have not been recognized in the financial statements and will be recorded as reduction of tax expense when realized.
	The non-refundable investment tax credits expire as follows (in thousands):



		FEDERAL ITC
	Expires in:
	2030	$	764

	2031	1,000

	2032	1,300

	2033	$	1,018

		$	4,082

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	Commitments and Contingencies
	The Company is committed under operating leases for the lease of its premises and certain office equipment but all such leases expire within the next twelve months. Future minimum annual payments required under these commitments are as follows (in thousands):


		Minimum
		Lease
		Payments
	2014	$	379

	Total lease expense for the years ended December 31, 2013 and 2012 was $0.4 million and $0.3 million , respectively.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
SUBSEQUENT EVENTS	Dec. 31, 2013
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	Subsequent Events
	The Company has evaluated subsequent events for potential recognition and disclosure through the date the financial statements are issued and has determined that no subsequent matter requires disclosure.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Basis of presentation	'
	Basis of presentation
	These consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (GAAP). These consolidated financial statements include the accounts of the Company, Methylgene and MethylGene US Inc. All significant inter-company transactions, balances, revenue and expenses have been eliminated upon consolidation.
	Mirati was incorporated under the laws of the State of Delaware on April 29, 2013. The Company was created to enter into an arrangement agreement described below.
	On May 8, 2013, the Company's Board of Directors approved and the Company entered into an arrangement agreement with MethylGene. Subject to the terms and conditions of the arrangement agreement, which was consummated on June 28, 2013, the shareholders of MethylGene received one share of the Company's common stock in exchange for every 50 common shares of MethylGene, which had the effect of a 50 for 1 reverse split of the common shares pursuant to a court-approved plan of arrangement under Section 192 of the Canada Business Corporations Act. Such transaction is referred to herein as the Arrangement. In addition, all outstanding options and warrants to purchase common shares of MethylGene became exercisable on a 50-for-1 basis for shares of our common stock, and a proportionate adjustment was made to the exercise price or conversion price, as applicable. The accompanying financial statements and notes to the financial statements give retroactive effect to the reverse split of our common stock for all periods presented. Upon completion of the Arrangement, MethylGene became the Company's wholly-owned subsidiary. The shares of the Company's common stock issued at the closing of the Arrangement were issued in reliance upon the exemption from registration under Section 3(A)(10) of the Securities Act of 1933, as amended.
Foreign currency translation	'
	Foreign currency translation
	Foreign currency transactions are initially recorded by the Company using the exchange rates prevailing at the date of the transaction. At the balance sheet date, monetary assets and liabilities denominated in foreign currencies are translated at the period-end rates of exchange. Non-monetary assets and liabilities are translated at the historical exchange rates. Exchange gains and losses arising from the translation of foreign currency items are included in other income (expense) in the consolidated statements of operations and comprehensive loss.
Cash and cash equivalents	'
	Cash and cash equivalents
	Cash is comprised of cash on hand and cash equivalents. Cash equivalents are comprised of short-term investment vehicles that are highly liquid and are readily convertible to known amounts of cash, which are subject to an insignificant risk of change in value, and have a maturity of less than 90 days from the date of purchase.
Short-term investments	'
	Short-term investments
	Short-term investments consist of debt securities and other investment vehicles that are highly liquid and are readily convertible to known amounts of cash, which are subject to an insignificant risk of change in value, and have an original maturity of greater than 90 days. The majority of the Company's short-term investments are classified as available-for-sale investments. Certain of the Company's investments were purchased by its Canadian subsidiary prior to the Arrangement and are designated as held for trading investments as the investment portfolio is actively managed and their performance is evaluated on a fair value basis, in accordance with a documented risk management or investment strategy.
	The Company's short-term investments are carried at their fair market value based upon quoted market prices for these or similar instruments at the balance sheet date. Unrealized gains and losses on available-for-sale securities are reported as a component of accumulated other comprehensive income in stockholders' equity until realized. Unrealized gains and losses on trading securities are included in other income (expense) on the statement of operations and comprehensive loss. Debt securities are adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization, as well as realized gains and losses, are included in other income (expense).
	We assess our investments for potential other-than-temporary impairment based on factors including the length of time and extent to which the fair market value has been below our cost basis, the current financial condition of the investee and our intent and ability to hold the investment for a sufficient period of time to allow for any anticipated recovery in market value. If we conclude that an other-than-temporary impairment exists, we recognize an impairment charge to reduce the investment to fair value and record the related charge as a reduction of interest to other income (expense), net. We determined there were no other-than-temporary declines in the value of short-term investments as of December 31, 2013 and 2012.
Property and equipment	'
	Property and equipment
	Property and equipment is stated at historical cost less accumulated depreciation and/or accumulated impairment losses, if any. Historical cost includes expenditures that are directly attributable to the acquisition of the items. Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. All other repairs and maintenance are charged to net loss during the financial period in which they are incurred.
	Depreciation of property and equipment is calculated using the straight-line method over the estimated useful lives of the assets, as follows:


	Computer equipment		3 years
	Office and other equipment		6 years
	Laboratory equipment		6 years
	Leasehold improvements		The lesser of the lease term or the life of the asset
	On disposal of property and equipment, the cost and related accumulated depreciation and impairments are removed from the consolidated financial statements and the net amount, less any proceeds, is included in net loss.
Impairment of long-lived assets	'
	Impairment of long-lived assets
	The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the long-lived asset, including its eventual residual value, is compared to the carrying value to determine whether impairment exists. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their estimated fair values. Fair value is estimated through discounted cash flow models to project cash flows from the asset.
Stock-based compensation	'
	Stock-based compensation
	The Company has a stock option compensation plan in which the fair value of stock options granted is determined at the date of the grant using the Black-Scholes option-pricing model and is expensed over the vesting period of the options. Stock-based compensation is recognized using the accelerated graded vesting method. In determining the expense, the Company deducts the number of options that are expected to be forfeited at the time of a grant and revises this estimate, if necessary, in subsequent years if actual forfeitures differ from those estimated.
Revenue recognition	'
	Revenue recognition
	From time to time the Company may recognize revenue from research collaboration agreements and licensing arrangements. Upfront product and technology license fees under multiple-element arrangements are deferred and recognized over the period of such services or performance if such arrangements require on-going services or performance. Non-refundable amounts received for substantive milestones are recognized upon achievement of the milestone. Any amounts received prior to satisfying these revenue recognition criteria are recorded as deferred revenue. For the years ended December 31, 2013 and 2012 the Company did not recognize any revenue from collaborative agreements.
Investment tax credits	'
	Investment tax credits
	The Company's accounts include claims for investment tax credits ("ITCs") relating to scientific research and experimental development activities of the Company. The qualification and recording of these activities for investment tax credit purposes are established by the Canadian federal and Provincial Tax Acts and are subject to audit by the taxation authorities. Refundable ITCs are reflected as reductions of expenses or reductions of the cost of the assets to which they relate when there is reasonable assurance that the assistance will be received and all conditions have been complied with. The non-refundable ITCs are carried forward for a time and will be recognized when it is more likely than not that the Company will become subject to Canadian federal taxes, at which time, said ITCs are applied as a reduction of tax expense.
Research and development expenses	'
	Research and development expenses
	Research and development expenditures are charged to net loss in the period in which they are incurred and comprise of the following types of costs incurred in performing research and development activities and those incurred in connection with research and development revenue: salaries and benefits, stock-based compensation expense, allocated overhead and occupancy costs, clinical trial and related clinical manufacturing costs, contract services, and other outside costs.
Income taxes	'
	Income taxes
	Income taxes have been accounted for using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applicable to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance against deferred tax assets is recorded if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. For uncertain tax positions that meet "a more likely than not" threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements.
Net loss per share	'
	Net loss per share
	Net loss per share is calculated by dividing the net loss of the Company by the weighted average number of shares of common stock outstanding during the year.
Fair value measurements	'
	Fair value measurements
	We have certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.
	The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance prioritizes the inputs used in measuring fair value into the following hierarchy:


	•	Level 1- Quoted prices (unadjusted) in active markets for identical assets or liabilities;


	•	Level 2- Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; and


	•	Level 3- Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.
Concentration of Credit Risk	'
	Concentration of Credit Risk
	The Company invests its excess cash in accordance with its investment policy. The Company's investments are comprised primarily of commercial paper and debt instruments of financial institutions, corporations, U.S. government-sponsored agencies and the U.S. Treasury. The Company mitigates credit risk by maintaining a well diversified portfolio and limiting the amount of investment exposure as to institution, maturity and investment type. Financial instruments that potentially subject the Company to significant credit risk consist principally of cash equivalents and short-term investments.
Segment Reporting	'
	Segment Reporting
	Operating segments are components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker for purposes of making decisions regarding resource allocation and assessing performance. To date, we have viewed our operations and managed our business as one segment operating primarily in the United States and Canada.
Use of Estimates	'
	Use of Estimates
	The preparation of the Company's consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts or revenue and expenses during the reporting period.
	Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. Estimates and assumptions are reviewed quarterly. All revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Schedule of estimated useful lives of assets	'
	Depreciation of property and equipment is calculated using the straight-line method over the estimated useful lives of the assets, as follows:


	Computer equipment		3 years
	Office and other equipment		6 years
	Laboratory equipment		6 years
	Leasehold improvements		The lesser of the lease term or the life of the asset
Schedule of potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive	'
	The following table presents potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive:


			Year ended
			December 31,
			2013			2012
	Common stock options		495			15,663

	Common stock warrants		644,426			690,046

	Total		644,921			705,709

Schedule of assets and liabilities that are measured at fair value on a recurring basis	'
	The following table summarizes the assets and liabilities measured at fair value on a recurring basis (in thousands):


		December 31,				Level 1				Level 2				Level 3
		2013
	Assets
	Cash and cash equivalents	$	14,235			$	12,431			$	1,804			$	—

	Short-term investments	47,835				—				47,835				—

		$	62,070			$	12,431			$	49,639			$	—


	Liabilities
	Warrant liability	$	33,407			$	—			$	—			$	33,407

		$	33,407			$	—			$	—			$	33,407



		December 31,				Level 1				Level 2				Level 3
		2012
	Assets
	Cash and cash equivalents	$	18,403			$	2,825			$	15,578			$	—

	Short-term investments	18,580				—				18,580				—

		$	36,983			$	2,825			$	34,158			$	—


	Liabilities
	Warrant liability	$	—			$	—			$	—			$	—

		$	—			$	—			$	—			$	—


Schedule of rollforward of the fair value of the liability which includes Level 3 measurements	'
	The following table presents a rollforward of the fair value of the warrant liability which includes Level 3 measurements (in thousands):


			Year ended December 31,
			2013				2012
	Warrant liability:
	Balance at beginning of year:		$	—			$	—

	Fair value upon reclassification of balance as of January 1, 2013		16,194				—

	Change in fair value of warrant liability		19,799				—
	included in net loss
	Fair value of warrants exercised		(2,586		)		—

	Balance at end of year:		$	33,407			$	—

Schedule of assumptions used to calculate fair value of the liability	'
	The fair value of the warrant liability was calculated utilizing the Black-Scholes option-pricing model, using the following assumptions:



			1-Jan-13						31-Dec-13
			2011 Warrants			2012 Warrants			2011 Warrants			2012 Warrants
	Risk-free interest rate		1.2	%		1.4	%		1.2	%		1.6	%

	Volatility		107.5	%		116.3	%		112	%		115.9	%

	Dividend yield		—			—			—			—

	Expected life in years		3.3			4.9			2.3			3.9

INVESTMENTS_Tables

INVESTMENTS (Tables)	12 Months Ended
	Dec. 31, 2013
Investments, Debt and Equity Securities [Abstract]	'
Schedule of Available-for-sale and Trading Securities Reconciliation	'
	The following tables summarize our short-term investments (dollars in thousands):


			As of December 31, 2013
		Maturity (in years)	Amortized cost	Gross unrealized gains	Gross unrealized losses		Estimated fair value
	U.S. Treasury securities and debt securities of U.S. Government agencies(1)	2 years or less	3,001	—	(3	)	2,998

	Corporate debt securities(1)	2 years or less	31,319	—	(22	)	31,297

	Commercial paper(1)	1 year or less	8,485	12	—		8,497

	Guaranteed investment certificates (2)	1 year or less	5,046	—	(3	)	5,043

			47,851	12	(28	)	47,835



			As of December 31, 2012
		Maturity (in years)	Amortized cost	Gross unrealized gains	Gross unrealized losses		Estimated fair value
	Term deposits (2)	1 year or less	7,036	—	—		7,036

	Commercial paper (2)	1 year or less	5,026	—	—		5,026

	Guaranteed investment certificates (2)	1 year or less	6,518	—	—		6,518

			18,580	—	—		18,580

	(1) Investments are designated as available-for-sale investments.
	(2) Investments are designated as trading investments.

OTHER_CURRENT_ASSETS_Tables

OTHER CURRENT ASSETS (Tables)	12 Months Ended
	Dec. 31, 2013
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'
Schedule of other current assets	'


	6. Other Current Assets	December 31,
		2013		2012
		(in thousands)
	Refundable research and development tax credits	809		593

	Interest and other receivables	306		507

	Prepaid expenses	667		779

	Commodity taxes and other	227		165

	Income taxes receivable	58		—

	Restricted cash	78		302

		$	2,145	$	2,346

PROPERTY_AND_EQUIPMENT_Tables

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Schedule of property and equipment	'


	7. Property and Equipment	December 31,
		2013			2012
		(in thousands)
	Computer equipment	$	1,534		$	1,421

	Office and other equipment	122			89

	Laboratory equipment	1,794			1,794

	Leasehold improvements	53			56

		$	3,503		$	3,360

	Less: Accumulated depreciation	(3,181		)	(3,027		)
		$	322		$	333

ACCOUNTS_PAYABLE_AND_ACCRUED_L1

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Schedule of accounts payable and accrued liabilities	'


	8. Accounts Payable and Accrued Liabilities	December 31,
		2013		2012
		(in thousands)
	Accounts payable	$	1,302	$	1,752

	Accrued expenses	2,335		2,754

	Accrued compensation and benefits	1,608		834

		$	5,245	$	5,340

RESTRUCTURING_Tables

RESTRUCTURING (Tables)	12 Months Ended
	Dec. 31, 2013
Restructuring and Related Activities [Abstract]	'
Restructuring and related costs	'
	Restructuring activities were reported as a separate line item in the accompanying consolidated statement of operations and comprehensive loss and were comprised of the following components (in thousands):


	Employee separation costs	$	911

	Facilities-related charges	50

	Asset impairments	40

	Other restructuring charges	24

	Total restructuring charges for the year ended December 31, 2013:	$	1,025

STOCKHOLDERS_EQUITY_Tables

STOCKHOLDERS' EQUITY (Tables)	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Schedule of Shares Reserved for Future Issuance	'
	As of December 31, 2013, the following shares were reserved for future issuance (in thousands):


		December 31,
		2013		2012
	Stock Option Plan	1,057		697

	Warrants to purchase common stock	2,540		2,733

	Employee Stock Purchase Plan	300		—

		3,897		3,430

Schedule of warrants issued and outstanding	'
	As of December 31, 2013 the following warrants for common stock were issued and outstanding:


	Issue date		Expiry date	Exercise price (stated in US Dollars as of 12/31/13)		Number of warrants outstanding
	April 4, 2011		April 4, 2016	$	7.01	1,461,541

	November 21, 2012		November 21, 2017	$	8.18	1,078,136

						2,539,677

STOCKBASED_COMPENSATION_STOCKB

STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of changes to the number of stock options granted by the Company and their weighted average exercise price	'
	The following table summarizes our stock option activity and related information for the year ended December 31, 2013:


		Number of		Weighted			Weighted-Average Remaining Contractual Term (years)	Aggregate Intrinsic Value (millions)
		options		average
				exercise
				price
	Options outstanding at December 31, 2012	559,812		$	15

	Granted	687,040		11.21

	Forfeited	(244,060	)	16.96

	Expired	(3,756	)	54.37

	Exercised	(40,534	)	13.9

	Options outstanding at December 31, 2013	958,502		$	11.18		6.6	$	5.4

	Options exercisable at December 31, 2013	251,981		$	10.57		5	$	1.7

	Options vested and expected to vest at December 31, 2013	896,778		$	11.18		6.5	$	5.1

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
	Total stock-based compensation expense by operating statement classification is presented below (in thousands):


		Year ended December 31,
		2013			2012
	Research and development expense	$	245		817

	General and administrative expense	2,947			1,192

		$	3,192		$	2,009

Schedule of assumptions used to estimate the fair value of options granted at the date of grant using the Black-Scholes option pricing model	'
	The assumptions used for the specified reporting periods and the resulting estimates of weighted-average estimated fair value per share of options granted during those periods are as follows:


			Year Ended
			December 31,
			2013	2012
	Risk-free interest rate		2.00%	1.20%
	Dividend yield		—%	—%
	Volatility factor		112.90%	116.40%
	Expected life in years		7	4.4
	Weighted average estimated fair value per share		$11.21	$9.00

OTHER_INCOME_EXPENSE_NET_Table

OTHER INCOME (EXPENSE), NET (Tables)	12 Months Ended
	Dec. 31, 2013
Other Income and Expenses [Abstract]	'
Summary of components of other income (expense), net	'
	The following table summarizes the components of other income (expense), net for the two years ended December 31, 2013 and 2012 (in thousands):


		Year ended December 31,
		2013			2012
	Interest and other income, net	$	203		$	240

	Loss on foreign exchange	(1,320		)	(12		)
		$	(1,117	)	$	228

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of components of income tax expense	'
	The provisions for income tax expense (benefit), to the Company's wholly-owned subsidiary, MethylGene US Inc., are as follows (in thousands):


		Year ended December 31,
	Current:	2013			2012
	Federal	$	(23	)	$	30

	State	—			9

	Canada	—			—

	Total current tax expense (benefit)	$	(23	)	$	39

Schedule of Effective Income Tax Reconciliation	'
	The differences between the effective income tax rate and the statutory tax rates during the years ended 2013 and 2012 are as follows (in thousands):


		Year Ended December 31,
		2013			2012
	Net loss before tax	$	(52,882	)	$	(20,247	)
	Statutory combined US federal and state tax rate (2012 - statutory combined Canadian federal and provincial tax rate)	39.83		%	26.9		%
	Statutory federal and provincial taxes	$	(21,063	)	$	(5,446	)
	Increase (decrease) in taxes recoverable resulting from:
	Effect of change in valuation allowance	8,537			5,145

	Non-deductible stock-based compensation	1,085			539

	Non-deductible warrant expenses for tax purposes	8,403			—

	Tax credits not taxable in Quebec	(96		)	(70		)
	Share issue costs - temporary difference	(184		)	(183		)
	Share issue costs - permanent difference	206			—

	Effect of foreign jurisdiction tax expense	—			39

	Differential in income tax rates of foreign subsidiary	3,059			—

	Other differences	30			15

	Income tax expense (benefit)	$	(23	)	$	39

Schedule of deferred tax	'
	The following table summarizes the significant components of our deferred tax assets (in thousands):


		DECEMBER 31,
	Deferred tax assets	2013			2012
	Assets
	Tangible and intangible depreciable assets	$	874		$	853

	Manufactured drug product inventory to be used in research	1,459			757

	Provisions	93			30

	Financing fees	445			628

	Net operating loss carry forwards	13,099			6,883

	Scientific research and experimental development expenditures	5,766			4,245

	Deferred tax assets	21,736			13,396

	Valuation allowance	(21,736		)	(13,396		)
	Net deferred tax assets	$	—		$	—

Schedule of expiration of NOLs	'
	The NOLs expire as follows (in thousands):


		US						Canada
		Federal			State			Federal		Provincial
	Expires in:
	2030	$	—		$	—		$	5,907	$	5,984

	2031	—			—			7,059		7,066

	2032	—			—			12,371		12,495

	2033	2,838			2,919			18,717		19,467

		$	2,838		$	2,919		$	44,054	$	45,012

Schedule of reconciliation of the beginning and ending gross amounts of unrecognized tax positions	'
	A reconciliation of the beginning and ending gross amounts of Canadian unrecognized tax positions adopted by the Company are as follows (in thousands):


		Federal						Provincial
		December 31,						December 31,
		2013			2012			2013		2012
	Unrecognized tax positions, beginning of year	$	159		$	157		$	5	$	3

	Gross decrease — current period tax positions	—			—			—		—

	Gross increase — current period tax positions	—			2			—		2

	Gross decrease — prior period tax positions	(48		)	—			—		—

	Gross increase — prior period tax positions	18			—			18		—

	Unrecognized tax positions, end of year	$	129		$	159		$	23	$	5

INVESTMENT_TAX_CREDITS_Tables

INVESTMENT TAX CREDITS (Tables)	12 Months Ended
	Dec. 31, 2013
INVESTMENT TAX CREDITS	'
Schedule of non-refundable investment tax credits expiration	'
	The non-refundable investment tax credits expire as follows (in thousands):



		FEDERAL ITC
	Expires in:
	2030	$	764

	2031	1,000

	2032	1,300

	2033	$	1,018

		$	4,082

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of future minimum annual payment required in the next year	'
	Future minimum annual payments required under these commitments are as follows (in thousands):


		Minimum
		Lease
		Payments
	2014	$	379

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	12 Months Ended					12 Months Ended		0 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Nov. 30, 2013	Jul. 26, 2013	Jan. 02, 2013	Dec. 31, 2013	Dec. 31, 2012	Jun. 28, 2013
	Dec. 31, 2013	Dec. 31, 2012	Nov. 30, 2013	Jul. 26, 2013	Jan. 02, 2013	Common stock warrants	Common stock warrants	MethylGene
Basis of presentation	'	'	'	'	'	'	'	'
Ratio of reverse split of the common shares	'	'	'	'	'	'	'	50
Exercisable ratio of outstanding options and warrants	'	'	'	'	'	'	'	50
Foreign currency translation	'	'	'	'	'	'	'	'
Net foreign exchange losses recognized in other income	$1,320,000	$12,000	'	'	'	'	'	'
Marketable securities and term deposits	'	'	'	'	'	'	'	'
Minimum original maturity period of marketable securities	'90 days	'	'	'	'	'	'	'
Reclassification of Warrants	'	'	'	'	'	'	'	'
Warrant liability	33,407,000	0	'	'	16,200,000	'	'	'
Initial fair value of warrants recorded within stockholders equity that was reversed	0	11,153,000	'	'	11,200,000	'	'	'
Change in fair value related to periods prior to January 1, 2013 recorded as an increase to accumulated deficit	'	'	'	'	5,000,000	'	'	'
Change in fair value of warrant liability included in net loss	19,799,000	0	'	'	'	19,799,000	0	'
Reclassification of Share-based compensation liability	'	'	'	'	'	'	'	'
Share-based compensation liability	'	'	'	1,100,000	'	'	'	'
Increase in additional paid-in capital due to reclassification of share-based compensation liability	300,000	'	'	'	'	'	'	'
Increase in stock compensation expense	1,400,000	'	'	'	'	'	'	'
Fair value of liability options	'	'	$2,200,000	'	'	'	'	'

SUMMARY_OF_SIGNIFICANT_ACCOUNT4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
	Dec. 31, 2012	Computer equipment	Office and other equipment	Laboratory equipment
Property and equipment	'	'	'	'
Estimated useful lives	'	'3 years	'6 years	'6 years
Impairment of long-lived assets	'	'	'	'
Impairment charges	$0	'	'	'

SUMMARY_OF_SIGNIFICANT_ACCOUNT5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)	Dec. 31, 2013	Dec. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Potentially dilutive securities not included in the calculation of diluted net loss per share (in shares)	644,921	705,709
Common stock options	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Potentially dilutive securities not included in the calculation of diluted net loss per share (in shares)	495	15,663
Common stock warrants	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Potentially dilutive securities not included in the calculation of diluted net loss per share (in shares)	644,426	690,046

SUMMARY_OF_SIGNIFICANT_ACCOUNT6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 4) (USD $)	Dec. 31, 2013	Jan. 02, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Jan. 02, 2013	Dec. 31, 2012
Liabilities	'	'	'
Warrant liability	$33,407	$16,200	$0
Recurring basis \| Total	'	'	'
Assets	'	'	'
Cash and cash equivalents	14,235	'	18,403
Short-term investments	47,835	'	18,580
Assets	62,070	'	36,983
Liabilities	'	'	'
Warrant liability	33,407	'	0
Liabilities	33,407	'	0
Recurring basis \| Level 1	'	'	'
Assets	'	'	'
Cash and cash equivalents	12,431	'	2,825
Short-term investments	0	'	0
Assets	12,431	'	2,825
Liabilities	'	'	'
Warrant liability	0	'	0
Liabilities	0	'	0
Recurring basis \| Level 2	'	'	'
Assets	'	'	'
Cash and cash equivalents	1,804	'	15,578
Short-term investments	47,835	'	18,580
Assets	49,639	'	34,158
Liabilities	'	'	'
Warrant liability	0	'	0
Liabilities	0	'	0
Recurring basis \| Level 3	'	'	'
Assets	'	'	'
Cash and cash equivalents	0	'	0
Short-term investments	0	'	0
Assets	0	'	0
Liabilities	'	'	'
Warrant liability	33,407	'	0
Liabilities	$33,407	'	$0

SUMMARY_OF_SIGNIFICANT_ACCOUNT7

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 5) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'	'
Change in fair value of warrant liability included in net loss	$19,799	$0
Common stock warrants	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'	'
Balance at beginning of year:	0	0
Fair value upon reclassification of balance as of January 1, 2013	16,194	0
Change in fair value of warrant liability included in net loss	19,799	0
Fair value of warrants exercised	-2,586	0
Balance at end of year:	$33,407	$0

SUMMARY_OF_SIGNIFICANT_ACCOUNT8

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 6)	0 Months Ended	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 6)	Jan. 02, 2013	Dec. 31, 2013
2011 Warrants	'	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'
Risk-free interest rate (as a percent)	1.20%	1.20%
Volatility (as a percent)	107.50%	112.00%
Dividend yield (as a percent)	0.00%	0.00%
Expected life	'3 years 3 months 18 days	'2 years 3 months 18 days
2012 Warrants	'	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'
Risk-free interest rate (as a percent)	1.40%	1.60%
Volatility (as a percent)	116.30%	115.90%
Dividend yield (as a percent)	0.00%	0.00%
Expected life	'4 years 10 months 24 days	'3 years 10 months 24 days

INVESTMENTS_Details

INVESTMENTS (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012
Schedule of Trading Securities and Other Trading Assets [Line Items]	'		'
Trading, Amortized cost	'		$18,580
Trading, Gross unrealized gains	'		0
Trading, Gross unrealized losses	'		0
Trading, Estimated fair value	'		18,580
Schedule of Available-for-sale Securities [Line Items]	'		'
Amortized cost	47,851		'
Gross unrealized gains	12		'
Gross unrealized losses	-28		'
Estimated fair value	47,835		'
U.S. Treasury securities and debt securities of U.S. Government agencies	'		'
Schedule of Available-for-sale Securities [Line Items]	'		'
Available-for-sale, maximum maturity period	'2 years		'
Available-for-Sale, Amortized cost	3,001	[1]	'
Available-for-Sale, Gross unrealized gains	0	[1]	'
Available-for-Sale, Gross unrealized losses	-3	[1]	'
Available-for-Sale, Estimated fair value	2,998	[1]	'
Corporate debt securities	'		'
Schedule of Available-for-sale Securities [Line Items]	'		'
Available-for-sale, maximum maturity period	'2 years		'
Available-for-Sale, Amortized cost	31,319	[1]	'
Available-for-Sale, Gross unrealized gains	0	[1]	'
Available-for-Sale, Gross unrealized losses	-22	[1]	'
Available-for-Sale, Estimated fair value	31,297	[1]	'
Commercial paper	'		'
Schedule of Trading Securities and Other Trading Assets [Line Items]	'		'
Trading, maximum maturity period	'		'1 year
Trading, Amortized cost	'		5,026	[2]
Trading, Gross unrealized gains	'		0	[2]
Trading, Gross unrealized losses	'		0	[2]
Trading, Estimated fair value	'		5,026	[2]
Schedule of Available-for-sale Securities [Line Items]	'		'
Available-for-sale, maximum maturity period	'1 year		'
Available-for-Sale, Amortized cost	8,485	[1]	'
Available-for-Sale, Gross unrealized gains	12	[1]	'
Available-for-Sale, Gross unrealized losses	0	[1]	'
Available-for-Sale, Estimated fair value	8,497	[1]	'
Term deposits	'		'
Schedule of Trading Securities and Other Trading Assets [Line Items]	'		'
Trading, maximum maturity period	'		'1 year
Trading, Amortized cost	'		7,036	[2]
Trading, Gross unrealized gains	'		0	[2]
Trading, Gross unrealized losses	'		0	[2]
Trading, Estimated fair value	'		7,036	[2]
Guaranteed investment certificates	'		'
Schedule of Trading Securities and Other Trading Assets [Line Items]	'		'
Trading, maximum maturity period	'1 year		'1 year
Trading, Amortized cost	5,046	[2]	6,518	[2]
Trading, Gross unrealized gains	0	[2]	0	[2]
Trading, Gross unrealized losses	-3	[2]	0	[2]
Trading, Estimated fair value	$5,043	[2]	$6,518	[2]

[1]	Investments are designated as available-for-sale investments.
[2]	Investments are designated as trading investments.

OTHER_CURRENT_ASSETS_Details

OTHER CURRENT ASSETS (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'	'
Refundable research and development tax credits	$809	$593
Interest and Other Receivables, Current	306	507
Prepaid expenses	667	779
Commodity taxes and other	227	165
Income taxes receivable	58	0
Restricted cash	78	302
Other current assets	$2,145	$2,346

PROPERTY_AND_EQUIPMENT_Details

PROPERTY AND EQUIPMENT (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Property and equipment	'	'
Property and equipment, gross	$3,503	$3,360
Less: Accumulated depreciation	-3,181	-3,027
Property and equipment, net	322	333
Depreciation expenses	171	123
Computer equipment	'	'
Property and equipment	'	'
Property and equipment, gross	1,534	1,421
Office and other equipment	'	'
Property and equipment	'	'
Property and equipment, gross	122	89
Laboratory equipment	'	'
Property and equipment	'	'
Property and equipment, gross	1,794	1,794
Leasehold improvements	'	'
Property and equipment	'	'
Property and equipment, gross	$53	$56

ACCOUNTS_PAYABLE_AND_ACCRUED_L2

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Payables and Accruals [Abstract]	'	'
Accounts payable	$1,302	$1,752
Accrued expenses	2,335	2,754
Accrued compensation and benefits	1,608	834
Total accounts payable and accrued liabilities	$5,245	$5,340

RESTRUCTURING_Details

RESTRUCTURING (Details) (USD $)	12 Months Ended
RESTRUCTURING (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Restructuring and Related Activities [Abstract]	'	'
Percentage of workforce positions eliminated	75.00%	'
Restructuring Cost and Reserve [Line Items]	'	'
Total restructuring charges for the year ended December 31, 2013:	$1,025,000	$0
Restructuring costs payable	300,000	'
Employee separation costs	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Total restructuring charges for the year ended December 31, 2013:	911,000	'
Restructuring costs payable in 2014	300,000	'
Facilities-related charges	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Total restructuring charges for the year ended December 31, 2013:	50,000	'
Restructuring costs payable in 2014	100,000	'
Asset impairments	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Total restructuring charges for the year ended December 31, 2013:	40,000	'
Other restructuring charges	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Total restructuring charges for the year ended December 31, 2013:	$24,000	'

STOCKHOLDERS_EQUITY_Details

STOCKHOLDERS' EQUITY (Details)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Class of Stock [Line Items]	'	'
Common stock reserved for future issuance (in shares)	3,897	3,430
Warrants to purchase common stock	'	'
Class of Stock [Line Items]	'	'
Common stock reserved for future issuance (in shares)	2,540	2,733
Stock Option Plan	'	'
Class of Stock [Line Items]	'	'
Common stock reserved for future issuance (in shares)	1,057	697
Employee Stock Purchase Plan	'	'
Class of Stock [Line Items]	'	'
Common stock reserved for future issuance (in shares)	300	0

STOCKHOLDERS_EQUITY_Details_2

STOCKHOLDERS' EQUITY (Details 2)

12 Months Ended

0 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Nov. 21, 2012

Dec. 31, 2013

Nov. 21, 2012

USD ($)

Common Stock

Private Placement April 2011

Private Placement November 2012

USD ($)

April 4, 2011 Warrants

USD ($)

CAD

November 21, 2012 Warrants

USD ($)

Common Stock

Common stock purchase warrant

Warrants - issued and outstanding

Exercise price (in dollars per share)

7.01

8.73

8.18

8.7

Number of warrants (in shares)

2,539,677

1,461,541

1,078,136

Gross proceeds from private placement

$26,100,000

Number of units issued in private placement (in shares)

3,593,819

Subscription price of units issued in a private placement (in dollars per share)

$7.28

7.25

Number of shares that can be purchased by each unit issued

0.3

Period during which warrants are exercisable

'5 years

Exercise price as percentage of subscription or market price

120.00%

Issuance costs of units

1,300,000

Assumptions used for calculation of fair value of warrants issued

Weighted average risk-free interest rate (as a percent)

1.34%

Dividend yield (as a percent)

0.00%

Volatility factor (as a percent)

115.50%

Expected life

'5 years

Fair value of warrants

4,942,000

4,900,000

Amount recorded as increase in common stock

$54,196,000

$19,886,000

$3,000

$4,000

$19,900,000

STOCKBASED_COMPENSATION_Detail

STOCK-BASED COMPENSATION (Details) (USD $)	12 Months Ended
STOCK-BASED COMPENSATION (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options available for issue	100,000	'
Intrinsic value of options exercised	$200,000	'
Cash received from exercise of stock options	500,000	'
Exercise of options (in shares)	40,534	0
Fair value of options vested	2,000,000	2,400,000
Capitalized costs	0	0
Tax benefit from compensation expense	0	'
Compensation cost not yet recognized	$4,900,000	'
Compensation cost not yet recognized, period for recognition	'1 year 10 months 24 days	'
Exercise price required percentage of fair market value	100.00%	'
Award vesting period	'4 years	'
Stock Option Plan \| Minimum	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock option contractual terms	'5 years	'
Stock Option Plan \| Maximum	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock option contractual terms	'7 years	'
2013 Plan \| Minimum	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock option contractual terms	'7 years	'
2013 Plan \| Maximum	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock option contractual terms	'10 years	'

STOCKBASED_COMPENSATION_Detail1

STOCK-BASED COMPENSATION (Details 2) (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'	'
Balance, beginning of year (in shares)	559,812	'
Granted (in shares)	687,040	'
Forfeited (in shares)	-244,060	'
Expired (in shares)	-3,756	'
Exercise of options (in shares)	-40,534	0
Balance, end of year (in shares)	958,502	559,812
Options exercisable, end of year (in shares)	251,981	'
Vested and unvested expected to vest options outstanding (in shares)	896,778	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]	'	'
Balance, beginning of year (in dollars per share)	$15	'
Granted (in dollars per share)	$11.21	'
Forfeited (in dollars per share)	$16.96	'
Expired (in dollars per share)	$54.37	'
Exercised (in dollars per share)	$13.90	'
Balance, end of year (in dollars per share)	$11.18	$15
Options exercisable, end of year (in dollars per share)	$10.57	'
Vested and unvested expected to vest options outstanding, Weighted-Average Exercise Price (in dollars per share)	$11.18	'
Options outstanding, Weighted-Average Remaining Contractual Term (years)	'6 years 7 months 6 days	'
Options exercisable, Weighted-Average Remaining Contractual Term (years)	'5 years	'
Options vested and expected to vest, Weighted-Average Remaining Contractual Term (years)	'6 years 6 months	'
Options outstanding, Aggregate Intrinsic Value	$5.40	'
Options exercisable, Aggregate Intrinsic Value	1.7	'
Options vested and expected to vest, Aggregate Intrinsic Value	$5.10	'

STOCKBASED_COMPENSATION_Detail2

STOCK-BASED COMPENSATION (Details 3) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expense	$3,192	$2,009
Research and development expense	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expense	245	817
General and administrative expense	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expense	$2,947	$1,192

STOCKBASED_COMPENSATION_Detail3

STOCK-BASED COMPENSATION (Details 4) (USD $)	12 Months Ended
STOCK-BASED COMPENSATION (Details 4) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'
Risk-free interest rate	2.00%	1.20%
Dividend yield	0.00%	0.00%
Volatility factor	112.90%	116.40%
Expected life in years	'7 years	'4 years 4 months 24 days
Weighted average estimated fair value per share	$11.21	$9

EMPLOYEE_BENEFIT_PLAN_Details

EMPLOYEE BENEFIT PLAN (Details) (USD $)	12 Months Ended
EMPLOYEE BENEFIT PLAN (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Compensation and Retirement Disclosure [Abstract]	'	'
Percentage of employee contributions matched	4.00%	'
Maximum employer contribution per employee	$2,500	'
Matching contribution amount	$34,600	$9,500

OTHER_INCOME_EXPENSE_NET_Detai

OTHER INCOME (EXPENSE), NET (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Other Income and Expenses [Abstract]	'	'
Interest and other income, net	$203	$240
Loss on foreign exchange	-1,320	-12
Other income (expense), net	($1,117)	$228

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
	ongoing_tax_audit	Dec. 31, 2012
Current income tax expense	'	'
Federal	($23,000)	$30,000
State	0	9,000
Canada	0	0
Total current tax expense (benefit)	-23,000	39,000
Deferred tax asset	'	'
Tangible and intangible depreciable assets	874,000	853,000
Manufactured drug product inventory to be used in research	1,459,000	757,000
Provisions	93,000	30,000
Financing fees	445,000	628,000
Net operating loss carry forwards	13,099,000	6,883,000
Scientific research and experimental development expenditures	5,766,000	4,245,000
Deferred tax assets	21,736,000	13,396,000
Valuation allowance	-21,736,000	-13,396,000
Net deferred tax assets	0	0
Additional disclosures	'	'
Amount of increase in valuation allowance	8,300,000	'
Share issue expenses not deducted	1,700,000	2,400,000
Reconciliation of the beginning and ending gross amounts of unrecognized tax positions	'	'
Unrecognized tax benefits that would not impact effective tax rate	200,000	200,000
Accrual for interest or penalties on tax matters	0	0
Number of ongoing tax audits	0	'
Canadian Federal	'	'
Additional disclosures	'	'
Scientific research and experimental development expenses deductible for income tax purposes	20,700,000	15,200,000
Net operating loss carry forwards (NOLs)	44,054,000	25,300,000
Reconciliation of the beginning and ending gross amounts of unrecognized tax positions	'	'
Unrecognized tax positions, beginning of year	159,000	157,000
Gross decrease b current period tax positions	0	0
Gross increase b current period tax positions	0	2,000
Gross decrease b prior period tax positions	-48,000	0
Gross increase b prior period tax positions	18,000	0
Unrecognized tax positions, end of year	129,000	159,000
Canadian Federal \| 2030	'	'
Additional disclosures	'	'
Net operating loss carry forwards (NOLs)	5,907,000	'
Canadian Federal \| 2031	'	'
Additional disclosures	'	'
Net operating loss carry forwards (NOLs)	7,059,000	'
Canadian Federal \| 2032	'	'
Additional disclosures	'	'
Net operating loss carry forwards (NOLs)	12,371,000	'
Canadian Federal \| 2033	'	'
Additional disclosures	'	'
Net operating loss carry forwards (NOLs)	18,717,000	'
Canadian Provincial	'	'
Additional disclosures	'	'
Scientific research and experimental development expenses deductible for income tax purposes	22,400,000	16,800,000
Net operating loss carry forwards (NOLs)	45,012,000	25,600,000
Reconciliation of the beginning and ending gross amounts of unrecognized tax positions	'	'
Unrecognized tax positions, beginning of year	5,000	3,000
Gross decrease b current period tax positions	0	0
Gross increase b current period tax positions	0	2,000
Gross decrease b prior period tax positions	0	0
Gross increase b prior period tax positions	18,000	0
Unrecognized tax positions, end of year	23,000	5,000
Canadian Provincial \| 2030	'	'
Additional disclosures	'	'
Net operating loss carry forwards (NOLs)	5,984,000	'
Canadian Provincial \| 2031	'	'
Additional disclosures	'	'
Net operating loss carry forwards (NOLs)	7,066,000	'
Canadian Provincial \| 2032	'	'
Additional disclosures	'	'
Net operating loss carry forwards (NOLs)	12,495,000	'
Canadian Provincial \| 2033	'	'
Additional disclosures	'	'
Net operating loss carry forwards (NOLs)	19,467,000	'
US Federal	'	'
Additional disclosures	'	'
Net operating loss carry forwards (NOLs)	2,838,000	0
US Federal \| 2030	'	'
Additional disclosures	'	'
Net operating loss carry forwards (NOLs)	0	'
US Federal \| 2031	'	'
Additional disclosures	'	'
Net operating loss carry forwards (NOLs)	0	'
US Federal \| 2032	'	'
Additional disclosures	'	'
Net operating loss carry forwards (NOLs)	0	'
US Federal \| 2033	'	'
Additional disclosures	'	'
Net operating loss carry forwards (NOLs)	2,838,000	'
US State	'	'
Additional disclosures	'	'
Net operating loss carry forwards (NOLs)	2,919,000	'
US State \| 2030	'	'
Additional disclosures	'	'
Net operating loss carry forwards (NOLs)	0	'
US State \| 2031	'	'
Additional disclosures	'	'
Net operating loss carry forwards (NOLs)	0	'
US State \| 2032	'	'
Additional disclosures	'	'
Net operating loss carry forwards (NOLs)	0	'
US State \| 2033	'	'
Additional disclosures	'	'
Net operating loss carry forwards (NOLs)	$2,919,000	'

INCOME_TAXES_Details_2

INCOME TAXES (Details 2) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Income Tax [Line Items]	'	'
Net loss before tax	($52,882)	($20,247)
Statutory combined US federal and state tax rate (2012 - statutory combined Canadian federal and provincial tax rate)	39.83%	26.90%
Income tax expense (benefit)	-23	39
United States Federal and State [Member]	'	'
Income Tax [Line Items]	'	'
Statutory federal and provincial taxes	-21,063	'
Effect of change in valuation allowance	8,537	'
Non-deductible stock-based compensation	1,085	'
Non-deductible warrant expenses for tax purposes	8,403	'
Tax credits not taxable in Quebec	-96	'
Share issue costs - temporary difference	-184	'
Share issue costs - permanent difference	206	'
Effect of foreign jurisdiction tax expense	0	'
Differential in income tax rates of foreign subsidiary	3,059	'
Other differences	30	'
Income tax expense (benefit)	-23	'
Canadian Federal and Provincial [Member]	'	'
Income Tax [Line Items]	'	'
Statutory federal and provincial taxes	'	-5,446
Effect of change in valuation allowance	'	5,145
Non-deductible stock-based compensation	'	539
Non-deductible warrant expenses for tax purposes	'	0
Tax credits not taxable in Quebec	'	-70
Share issue costs - temporary difference	'	-183
Share issue costs - permanent difference	'	0
Effect of foreign jurisdiction tax expense	'	39
Differential in income tax rates of foreign subsidiary	'	0
Other differences	'	15
Income tax expense (benefit)	'	$39

INVESTMENT_TAX_CREDITS_Details

INVESTMENT TAX CREDITS (Details) (USD $)	12 Months Ended
INVESTMENT TAX CREDITS (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Canadian Provincial	'	'
INVESTMENT TAX CREDITS	'	'
Refundable ITCs recorded as a reduction of research and development expenditures	$900,000	$1,700,000
Favorable adjustment included in refundable ITCs resulting from a statutory audit	1,100,000	1,100,000
Canadian Federal	'	'
INVESTMENT TAX CREDITS	'	'
Non-refundable ITCs related to scientific research and development expenditures	4,082,000	3,100,000
Canadian Federal \| 2030	'	'
INVESTMENT TAX CREDITS	'	'
Non-refundable ITCs related to scientific research and development expenditures	764,000	'
Canadian Federal \| 2031	'	'
INVESTMENT TAX CREDITS	'	'
Non-refundable ITCs related to scientific research and development expenditures	1,000,000	'
Canadian Federal \| 2032	'	'
INVESTMENT TAX CREDITS	'	'
Non-refundable ITCs related to scientific research and development expenditures	1,300,000	'
Canadian Federal \| 2033	'	'
INVESTMENT TAX CREDITS	'	'
Non-refundable ITCs related to scientific research and development expenditures	$1,018,000	'

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	12 Months Ended
COMMITMENTS AND CONTINGENCIES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Future minimum annual payments	'	'
2014	$379,000	'
Operating Leases, Rent Expense, Net [Abstract]	'	'
Lease expense	$400,000	$300,000